SystemOnline
WorkflowsClopidogrel + Warfarin + Simvastatin
Reference PopulationsAFR EUR EAS SAS AMR
1000G SamplesPhase-3 (n=2504)
Decision EngineDeterministic PGx
Evidence LayerV1–V10 / R1–R12 / U1–U9
Export StackCSV PDF FHIR
Data ModeResearch Simulation
GovernanceAudit Enabled
Engineanukriti-pgx-core==0.2.1
SystemOnline
WorkflowsClopidogrel + Warfarin + Simvastatin
Reference PopulationsAFR EUR EAS SAS AMR
1000G SamplesPhase-3 (n=2504)
Decision EngineDeterministic PGx
Evidence LayerV1–V10 / R1–R12 / U1–U9
Export StackCSV PDF FHIR
Data ModeResearch Simulation
GovernanceAudit Enabled
Engineanukriti-pgx-core==0.2.1
SystemOnline
WorkflowsClopidogrel + Warfarin + Simvastatin
Reference PopulationsAFR EUR EAS SAS AMR
1000G SamplesPhase-3 (n=2504)
Decision EngineDeterministic PGx
Evidence LayerV1–V10 / R1–R12 / U1–U9
Export StackCSV PDF FHIR
Data ModeResearch Simulation
GovernanceAudit Enabled
Engineanukriti-pgx-core==0.2.1
SystemOnline
WorkflowsClopidogrel + Warfarin + Simvastatin
Reference PopulationsAFR EUR EAS SAS AMR
1000G SamplesPhase-3 (n=2504)
Decision EngineDeterministic PGx
Evidence LayerV1–V10 / R1–R12 / U1–U9
Export StackCSV PDF FHIR
Data ModeResearch Simulation
GovernanceAudit Enabled
Engineanukriti-pgx-core==0.2.1
Anukriti logo

Anukriti

Gallery · Recognition · Programs

Milestones &
Recognitions

A running record of the awards, accelerator programs, and external validation Anukriti has earned on its way from research prototype to population-aware trial intelligence platform.

Recognitions

02

AWS AIdeas + Nova Prize

Programs

01

Base44 Cohort 1

Recognition
AWS AIdeas winner email confirmation from AWS Builder Engagement
Winner confirmation — AWS Builder Engagement, May 2026
01 · May 2026

AWS AIdeas Winner — Top 20 Globally

1 of 20 winners selected from 10,000+ ideas across 115 countries

Anukriti was selected as one of 20 global winners in the AWS AIdeas competition. The contest received over 10,000 submissions from builders across 115 countries. Anukriti's population-aware pharmacogenomics approach — pairing a deterministic CPIC + PharmVar engine with explainable AI narration — was recognized for its potential to reduce trial-stage failure rates by surfacing ancestry-dependent risks early.

  • verified10,000+ submissions, 115 countries
  • verified20 global winners selected
  • verifiedFeatured on AWS Builder Center
  • verifiedPopulation-aware pharmacogenomics approach
Hackathon Prize
Devpost winner email confirming Anukriti AI won Bonus Blog Post Prize in Amazon Nova AI Hackathon
Winner email — Devpost · Amazon Nova AI Hackathon
02 · Apr 2026

Amazon Nova AI Hackathon — Bonus Blog Post Prize

Anukriti AI won $200 in AWS credits on Devpost

Anukriti AI won the Bonus Blog Post Prize in the Amazon Nova AI Hackathon on Devpost. The prize included $200 in AWS credits, awarded for the project write-up and build quality showcasing Anukriti as an AI-powered simulation platform using Amazon Nova models.

  • verifiedWinner: Bonus Blog Post Prize
  • verified$200 AWS Credits awarded
  • verifiedProject published on Devpost
  • verifiedAmazon Nova + Bedrock architecture
Accelerator
Base44 Accelerator Cohort 1 founder card for Abhimanyu R B, CEO of Anukriti
Base44 Accelerator · Cohort 1 founder card
03 · May 2026

Base44 Accelerator — Cohort 1 Founder

33 startups selected from 100+ applicants for the first cohort

Anukriti was selected for Cohort 1 of the Base44 Accelerator program — one of 33 startups chosen from over 100 applicants. The cohort brings together founders building AI-native products and provides structured mentorship, distribution support, and runway to ship deeper product layers.

  • verifiedCohort 1 — first ever Base44 cohort
  • verified33 founders selected from 100+ applicants
  • verifiedAI-native product track
  • verifiedMentorship + distribution support
flag

More chapters loading…

Pilot launches, partnerships, conference talks, and research collaborations will be added here as Anukriti progresses.

Anukriti is a research simulation platform. Awards, programs, and external recognition listed here do not constitute clinical validation.